Medpace: Accelerating biotech research and raising the 2025 forecast. AI disruption could significantly increase business volume!
Reading Time: 2 minutes
Medpace (MEDP) is a global contract research organization (CRO) aimed at accelerating the development of medications. The company acts as a full-service partner for the conduct of clinical trials of all phases, particularly for small and medium-sized biotech firms with a target market of USD 29 billion. The service portfolio includes study planning, clinical monitoring, biometric evaluation, and integrated laboratory services (central, bioanalytical, and core labs). Can AI become a new growth engine for Medpace? Key growth drivers include the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
